ACADIA Pharmaceuticals Inc(ACAD:NSD) HC Wainwright raises the target price to $25

STA Research
by: STA Research
ACADIA Pharmaceuticals Inc

HC Wainwright maintains ACADIA Pharmaceuticals Inc with a Buy rating and raises the target price to $25 from $20 on the company’s stock.

Goldman Sachs lowers the target price on ACADIA Pharmaceuticals Inc to $15 from $20 and maintains a Neutral rating.

Based on the ACADIA Pharmaceuticals Inc stock forecasts from 14 analysts, the average analyst target price for ACADIA Pharmaceuticals Inc is USD 20.77 over the next 12 months. ACADIA Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of ACADIA Pharmaceuticals Inc is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, ACADIA Pharmaceuticals Inc’s stock price was USD 16.62ACADIA Pharmaceuticals Inc’s stock price has changed by +17.79% over the past week, +5.59% over the past month and -13.35% over the last year.

What we like:

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What we don’t like:

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.